Aandelen in “Productie van biologische producten”

Aandeel Datum Koers Evolutie
vlag Beam Therapeutics Inc 9/09 25,175 USD
-6,17% 		-6,17%
vlag Bio-Techne Corp 9/09 72,250 USD
-0,08% 		-0,08%
vlag Biocryst Pharmaceuticals Inc. 9/09 8,805 USD
-2,87% 		-2,87%
vlag Biogen 9/09 210,730 USD
-0,83% 		-0,83%
vlag BioNTech SE 9/09 98,130 USD
-0,54% 		-0,54%
vlag Brainstorm Cell Therapeutics, Inc. 9/09 1,000 USD
+1,01% 		+1,01%

Nieuws over “Productie van biologische producten”

9/09 · AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE · Persbericht

9/09 · AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE · Persbericht

9/09 · Are FULC, WEAV, TECH Obtaining Fair Deals for their Shareholders? · Persbericht

9/09 · Olie nadert $100 en wakkert rentevrees aan · LYNX

De internationale aandelenmarkten beginnen woensdag voorzichtig, waarbij de verdere stijging van de olieprijs het dominante thema blijft. De escalatie tussen de Verenigde Staten en Iran heeft Brent richting $100 per vat...

9/09 · GENFIT Highlights Long-Term Commercial Opportunity for its MASH Diagnostics Technology · Persbericht

8/09 · Berger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA) · Persbericht

8/09 · IMDELLTRA® IN COMBINATION WITH IMFINZI® DEMONSTRATED LANDMARK IMPROVEMENT IN OVERALL SURVIVAL IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER · Persbericht

8/09 · REGENXBIO to Participate in Upcoming Investor Conferences · Persbericht

4/09 · Brusselse beurs: het wankele huis van Atenor · Tijd.be (€)

De Europese beurzen doen het kalmpjes aan. UCB en Argenx wegen op de Bel20, terwijl de koers van Atenor naar een dieptepunt zakt.

4/09 · Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) · Persbericht

3/09 · DBV Technologies to Participate in Upcoming September Investor Conferences · Persbericht

3/09 · Monthly information on share capital and company voting rights · Persbericht

3/09 · GENFIT to Host Virtual KOL Event Focused on MASH Diagnostics on September 9, 2026   · Persbericht

2/09 · Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of August 31, 2026 · Persbericht

2/09 · Novavax to Participate in September Investor Conferences · Persbericht

2/09 · AMGEN TO PRESENT AT THE 2026 WELLS FARGO HEALTHCARE CONFERENCE · Persbericht

2/09 · Neurocrine Biosciences to Present at Upcoming Investor Conferences in September · Persbericht

2/09 · Halozyme to Participate at Upcoming Investor Conferences · Persbericht

1/09 · Cellectis Announces Participation in Upcoming Investor Conferences · Persbericht

1/09 · Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC) · Persbericht

1/09 · Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals · Persbericht

Mijn selecties